RESONETICS
The company designs, builds and services its own laser micromachining workstations rather than relying on offthe-shelf machines. It says more than 500 of these systems are installed worldwide, producing features down to the micron level, or one thousandth of a millimetre.
Resonetics’ s toolkit includes ultrafast femtosecond and picosecond lasers, which fire pulses lasting quadrillionths or trillionths of a second. These remove material so quickly that the surrounding metal suffers minimal heat damage, which is critical for parts implanted in the body.
The workstations also carry in-line process controls, including machine vision for alignment and inspection and autofocus sensors that detect a part’ s height. At this scale, precision depends as much on sensing and measurement as on the cutting tool itself.
Materials are the other half of the story. In 2023, Resonetics completed a reported US $ 900m acquisition of Memry and SAES Smart Materials, the medical nitinol businesses of Italian company SAES Getters.
Nitinol is a nickel-titanium alloy that returns to a preset shape and flexes without breaking, making it ideal for stents and heart valve frames. The deal gave Resonetics the ability to make nitinol from raw nickel and titanium, then convert it into wire, tube and sheet.
Kevin Kelly, President and CEO of Resonetics, stated when the deal completed:“ Nitinol is a key growth driver for Resonetics. We’ re excited to expand upon our existing nitinol processing capabilities so that we can provide a more complete and cost-effective nitinol solution.”
Buying in capability Since 2025, Resonetics has added a string of niche manufacturing technologies through acquisition. In May 2025, it bought assets from Medical Component Specialists to set up nitinol gun drilling, the first stage in producing seamless implant-grade nitinol tubing.
Eden Holdings followed in September 2025, bringing precision injection moulding, micro-moulding and micromachining. That allows Resonetics to make tiny plastic parts alongside its metal components.
The biggest move came in March 2026, when Resonetics completed its acquisition of Resolution Medical, a device design and manufacturing firm based in Minnesota. The deal added more than 240 employees, including at least 100 engineers.
Resolution Medical brought expertise in biosimulation, which uses computer models to predict how a device will behave in the body before it is built. It also added new product introduction and cleanroom assembly for higher-risk Class II and Class III devices.
Resonetics now reports 18 facilities and more than 3,000 employees across the US, Canada, Costa Rica, Israel and Switzerland, and is backed by private equity firms Carlyle and GTCR. For Kevin, the logic of the deal was driven by what customers increasingly demand.
6 November 2026